DIA 48th Annual Meeting
Click here to go to the previous page
Asian Regulatory Agencies Relocated into Biotech Science Park as a Strategy for Global Drug Development
Track
:
Track 02: Project/Portfolio Management and Strategic Planning
Program Code:
304
Date:
Wednesday, June 27, 2012
Time:
8:00 AM to 9:30 AM
EST
CHAIR
(S):
Herng-Der Chern, Center for Drug Evaluation, Taiwan, Taiwan Romi Singh, Amgen Inc., United States
PRESENTER
(S):
Ling-Mei Wang, Industrial Technology Research Institute, Taiwan
Tsuyoshi Ando, Pharmaceuticals and Medical Devices Agency (PMDA), Japan Romi Singh, Amgen Inc., United States
Description
Asian regulatory agencies, like the Singapore Health Sciences Authority and the Korea FDA, were relocated into biotech science parks, and Taiwan has developed a strategy of a supra-incubator center to become a proactive supporter of global drug development. In this session, we will examine these strategies and outcomes of new drug development from Singapore, Korea, and Taiwan.
Learning Objectives:
Describe the supra-incubation center in Taiwan as a strategic infrastructure for global drug development
Appraise the benefit of regulatory agencies inside biotech science parks in Korea and Singapore
Identify regulatory science as a critical factor for global drug development.
Learning Objectives:
Describe the supra-incubation center in Taiwan as a strategic infrastructure for global drug development
Appraise the benefit of regulatory agencies inside biotech science parks in Korea and Singapore
Identify regulatory science as a critical factor for global drug development.
This session is a part of:
Handout Online
